STOCK TITAN

WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

WuXi Biologics announced a USD$1.4 billion investment in a new CRDMO center in Singapore, enhancing its manufacturing capacity by adding 120,000L biomanufacturing capabilities by 2026. This center is poised to employ 1,500 staff and strengthen the company's global supply chain as part of its Global Dual Sourcing strategy. Supported by Singapore’s Economic Development Board, this investment emphasizes Singapore's role as a biopharmaceutical hub. WuXi Biologics aims to foster the local biotech ecosystem and support global healthcare partners.

Positive
  • Investment of USD$1.4 billion for a new CRDMO center in Singapore.
  • Addition of 120,000L biomanufacturing capacity by 2026.
  • Anticipated employment of 1,500 staff, boosting local economy.
  • Strengthens global supply chain to meet increasing client demand.
Negative
  • None.
  • This investment will establish a cutting-edge, fully integrated CRDMO center in Singapore, including a research and development service center and large-scale drug substance and drug product manufacturing facilities for biologics
  • The investment strengthens WuXi Biologics' global research, development and manufacturing network with more robust nodes to meet the growing demand from clients worldwide for end-to-end services, and continues to enable its Global Dual Sourcing strategy

SINGAPORE, July 19, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today announced a 10-year USD$1.4 billion (S$2 billion) investment plan to expand the company's research, development, and large-scale drug substance and drug product (DS/DP) manufacturing capacity and capabilities in Singapore. This new site will add 120,000L biomanufacturing capacity to WuXi Biologics' global network by 2026 and is anticipated to employ 1,500 research, development and manufacturing staff when complete.

Following the momentum of continued investments in the U.S., Ireland, Germany and China, this new addition in Singapore will become a critical part of the robust global supply chain network WuXi Biologics has established to fully meet the needs of global clients. The center will also reinforce WuXi Biologics' Global Dual Sourcing strategy, which ensures that customer projects can be fulfilled at multiple facilities globally to mitigate potential risks.

WuXi Biologics' investment plan is supported by the Singapore Economic Development Board (EDB). "We warmly welcome WuXi Bio's plan," said Dr. Beh Swan Gin, Chairman of EDB. "The investments will establish Singapore as a significant node in the company's global research, development and manufacturing network. It is a testament to Singapore's position as a global biopharmaceutical hub, and will strengthen our attractiveness to biotech innovators and start-ups."

Dr. Chris Chen, CEO of WuXi Biologics, commented, "Singapore has established itself as one of the most advanced pharmaceutical hubs in the world. As a trusted partner to global healthcare companies and a strong contributor to the local community, WuXi Biologics' investment in the new CRDMO center will enhance the sustainable growth and success of the Singapore biotech ecosystem and enable the global biologics industry with a more robust supply chain. With the support of EDB and our local partners in Singapore, WuXi Biologics looks forward to moving ahead with this important project to enable global partners and benefit patients worldwide."

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide.

With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of April 30, 2022, WuXi Biologics is supporting 526 integrated client projects, including nine in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Cision View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-plans-to-build-a-comprehensive-crdmo-center-in-singapore-301588939.html

SOURCE WuXi Biologics

FAQ

What is the investment plan announced by WuXi Biologics in Singapore?

WuXi Biologics announced a USD$1.4 billion investment plan to establish a CRDMO center in Singapore, enhancing its manufacturing capacity.

How will the new CRDMO center in Singapore impact WuXi Biologics' operations?

The CRDMO center is expected to add 120,000L biomanufacturing capacity and employ 1,500 staff, strengthening WuXi Biologics' global supply chain.

When is the new manufacturing facility in Singapore expected to be completed?

The new manufacturing facility is anticipated to be operational by 2026.

What is WuXi Biologics' Global Dual Sourcing strategy?

The Global Dual Sourcing strategy ensures that customer projects can be fulfilled at multiple facilities globally, mitigating potential risks.

What support has WuXi Biologics received for its investment in Singapore?

The investment plan is supported by the Singapore Economic Development Board.

WUXI BIOLOGICS UNSP/ADR

OTC:WXXWY

WXXWY Rankings

WXXWY Latest News

WXXWY Stock Data

8.92B
2.05B
0%
Biotechnology
Healthcare
Link
United States of America
Wuxi